0001209191-20-017726.txt : 20200310
0001209191-20-017726.hdr.sgml : 20200310
20200310165848
ACCESSION NUMBER: 0001209191-20-017726
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200308
FILED AS OF DATE: 20200310
DATE AS OF CHANGE: 20200310
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Erck Stanley C
CENTRAL INDEX KEY: 0001342826
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-26770
FILM NUMBER: 20702526
MAIL ADDRESS:
STREET 1: 20 FIRSTFIELD ROAD, #250
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NOVAVAX INC
CENTRAL INDEX KEY: 0001000694
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 222816046
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 21 FIRSTFIELD ROAD
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
BUSINESS PHONE: 240-268-2000
MAIL ADDRESS:
STREET 1: 21 FIRSTFIELD ROAD
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-03-08
0
0001000694
NOVAVAX INC
NVAX
0001342826
Erck Stanley C
C/O NOVAVAX, INC.
21 FIRSTFIELD ROAD
GAITHERSBURG
MD
20878
1
1
0
0
President and CEO
Common Stock
2020-03-08
4
M
0
6072
A
22486
D
Common Stock
2020-03-08
4
F
0
1992
12.48
D
20494
D
Restricted Stock Units
2020-03-08
4
M
0
6072
0.00
D
Common Stock
6072
0
D
Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on satisfaction of both (1) a time-based vesting requirement, pursuant to which one hundred percent (100%) of the RSUs vested on the first anniversary of the March 8, 2019 grant date subject to continued employment through such vesting date; and (2) a performance-based vesting requirement, pursuant to which one hundred percent (100%) of the RSUs vested based on the Company's achievement of a regulatory milestone associated with NanoFlu on or before September 30, 2019.
/s/ John A. Herrmann III, Attorney-in-Fact
2020-03-10